BioNTech stock tumbles 10% on cancer trial termination

BioNTech stock experienced a 10% decline following the termination of a cancer trial. This drop was triggered by the failure of the mRNA trial, which has drawn significant attention to the contrast between the company's current results and those of Moderna. The market reaction reflects the impact of the trial's end on investor confidence in BioNTech's oncology pipeline, as the company navigates the challenges associated with developing mRNA-based treatments for cancer compared to its competitors.